STOCK MARKET BSE NSE

Jenburkt Pharma launches COVID-19 drug at Rs 39 per tablet

The company hopes that the easy accessibility and affordable price point of an effective treatment such as Favivent will offer Indian citizens a timely solution.

Published: 24th July 2020 07:22 PM  |   Last Updated: 24th July 2020 07:22 PM   |  A+A-

coronavirus, PPE, COVID 19

More than 300 healthcare workers, including doctors have tested positive across the State and OPD visit to three premier health institutions. (Photo | Shekhar Yadav, EPS)

By PTI

NEW DELHI: Drug firm Jenburkt Pharmaceuticals on Friday said it has launched antiviral drug Favipiravir under the brand name 'Favivent' for the treatment of mild to moderate COVID-19 symptoms at a price of Rs 39 per tablet.

The tablet will be available in 200 mg strength in the form of a strip of 10 tablets, it added.

The drug will be manufactured at a pharmaceutical plant in Telangana with the highest safety and manufacturing protocols in place, Jenburkt Pharmaceuticals said in a statement.

On Thursday, pharma company Brinton Pharmaceuticals had said it will be selling Favipiravir under the brand name 'Faviton' at a maximum retail price of Rs 59 per tablet.

Pharma major Glenmark Pharmaceuticals is already selling Favipiravir under the brand name 'FabiFlu' at a price of Rs 75 per tablet.

Earlier this year, the Drug Controller General of India (DCGI) had approved the use of Favipiravir -- an antiviral drug developed in Japan and commonly used for treating influenza -- for the treatment of mild to moderate cases of COVID-19 in India.

"Given the current scenario of grave health concerns and economic challenges surrounding COVID-19 in India, if we as a pharmaceutical company cannot make a significant positive difference to the society, our company's very existence is inconsequential," Jenburkt Pharmaceuticals Chairman and MD Ashish U Bhuta said.

The company hopes that the easy accessibility and affordable price point of an effective treatment such as Favivent will offer Indian citizens a timely, much-needed therapeutic solution, he added.

Shares of Jenburkt Pharmaceuticals closed at Rs 391.90 per scrip on BSE, down 1.05 per cent.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp